Dual Antithrombotic Therapy Targeting Residual Risk for Atherosclerotic Cardiovascular Disease: Does Body Mass Index Matter?

J Am Coll Cardiol. 2021 Feb 9;77(5):526-528. doi: 10.1016/j.jacc.2020.12.005.

Authors

Karlyn Martin¹, Sadiya S Khan²

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address: [email protected].
² Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

PMID: 33538249
DOI: 10.1016/j.jacc.2020.12.005

No abstract available

Keywords: DOAC; anticoagulant; cardiovascular risk; obesity; prevention; rivaroxaban.

Publication types

Editorial
Comment

MeSH terms

Body Mass Index
Cardiovascular Diseases* / drug therapy
Fibrinolytic Agents* / therapeutic use
Humans
Rivaroxaban
Warfarin

Substances

Fibrinolytic Agents
Warfarin
Rivaroxaban